We recently demonstrated30 a dose-response effect from unmodified human bone marrow CD34+ (hBM34+) cells intravenously administered into symptomatic ALS mice, resulting in delayed disease progression, preserved motor neuron survival, lessened macro- and microgliosis, maintained perivascular astrocyte end-feet, and reduced permeability of spinal cord capillaries. Here, CD34 is linked to amyotrophic lateral sclerosis.